Ignite Creation Date:
2025-12-24 @ 2:06 PM
Ignite Modification Date:
2026-02-20 @ 6:04 PM
Study NCT ID:
NCT03113695
Status:
COMPLETED
Last Update Posted:
2022-07-05
First Post:
2017-04-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
Sponsor:
University of California, San Diego
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-12-20
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-02
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-10
First Submit QC Date:
None
Study First Post Date:
2017-04-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-01
Last Update Post Date:
2022-07-05
Last Update Post Date Type:
ACTUAL